CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 83 enrolled
Drug / intervention
Naltrexone +1 moredrug
Likely dose
Naltrexone 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00366626
NCT00366626Phase 4Completed
CompareCT.gov

Alcohol Research Center Grant. Component #1: Naltrexone Effects on Alcohol Reactivity and Consumption, Evaluating the Genetic Variability of Naltrexone Response

Medical University of South Carolina·interventional·Posted Aug 21, 2006·Updated Jun 5, 2017

In Brief

A Phase 4 clinical trial evaluating Naltrexone and Placebo for Alcohol Dependence. Completed, enrolled 83 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether naltrexone (an opiate blocking agent approved for the treatment of alcohol dependence) is more effective in the reduction of alcohol craving and drinking compared to placebo in individuals with particular genetic predisposition.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcohol Dependence
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 21, 2006
Enrollment StartApr 1, 2006
Primary CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 19.9 years ago

Interventions

Naltrexonedrug

Naltrexone (25 mg/day for days 1-2 and 50 mg/day for days 3-7)

Placebodrug

Placebo for 7 days matched to Naltrexone